Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

209
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

218
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
218
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

246
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
246
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

275
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
275
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

235
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
235

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In-office compounding of buffered lidocaine and epinephrine - A stability and safety review.

Journal of the American Academy of Dermatology·2026
Same author

Randomized placebo-controlled trial of feline-origin <i>Enterococcus hirae</i> probiotic effects on preventative health and fecal microbiota composition of fostered shelter kittens.

Frontiers in veterinary science·2022
Same author

Honey bee medicine for veterinarians and guidance for avoiding violative chemical residues in honey.

Journal of the American Veterinary Medical Association·2021
Same author

Availability of Didactic and Experiential Learning Opportunities in Veterinary Practice at US Pharmacy Programs.

American journal of pharmaceutical education·2021
Same author

Characterization of Veterinary Pharmacy and Pharmacology Literature and its Availability to Pharmacy Education.

American journal of pharmaceutical education·2020
Same author

Baseline Knowledge of Potential Pet Toxins among the US General Public.

Journal of applied animal welfare science : JAAWS·2018
Same journal

RETRACTED: Meligy et al. Therapeutic Potential of Mesenchymal Stem Cells Versus Omega n - 3 Polyunsaturated Fatty Acids on Gentamicin-Induced Cardiac Degeneration. <i>Pharmaceutics</i> 2022, <i>14</i>, 1322.

Pharmaceutics·2026
Same journal

Correction: Mohite et al. Bioactive Compound-Fortified Nanomedicine in the Modulation of Reactive Oxygen Species and Enhancement of the Wound Healing Process: A Review. <i>Pharmaceutics</i> 2025, <i>17</i>, 855.

Pharmaceutics·2026
Same journal

Metal Nanoparticle-Reinforced Hydrogels Applied in the Inhibition of Clinical Pathogens: Structural Features, Mechanisms, and Biomedical Prospects.

Pharmaceutics·2026
Same journal

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Cipepofol Across Diverse Clinical Populations.

Pharmaceutics·2026
Same journal

Artificial Intelligence in Nanopharmaceutical Development: From Predictive Design to Clinical Translation.

Pharmaceutics·2026
Same journal

Textilinin-1, a Snake Venom-Derived Kunitz-Type Protease Inhibitor, Accelerates Wound Healing Through Anti-Inflammatory, Antibacterial, and Pro-Regenerative Activities.

Pharmaceutics·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.0K

Veterinary Compounding: Regulation, Challenges, and Resources.

Gigi Davidson1

  • 1Clinical Pharmacy Services, North Carolina State University, College of Veterinary Medicine, Raleigh, NC 27607, USA. gsdavid2@ncsu.edu.

Pharmaceutics
|January 12, 2017
PubMed
Summary
This summary is machine-generated.

Veterinary drug compounding fills therapeutic gaps but carries risks due to quality issues and regulatory challenges. Ensuring high-quality animal compounds requires adherence to standards and validated formulas.

Keywords:
compoundingveterinaryveterinary pharmacy

More Related Videos

Surgical Model for Single-Staged Tissue-Engineered Urothelial Tubes in Minipigs
04:05

Surgical Model for Single-Staged Tissue-Engineered Urothelial Tubes in Minipigs

Published on: July 5, 2024

799
Large Volume Blood Collection from Swine for In Vitro Applications: Use of Intracardiac Cannulation and a Vacuum Pump as a Terminal Procedure
04:09

Large Volume Blood Collection from Swine for In Vitro Applications: Use of Intracardiac Cannulation and a Vacuum Pump as a Terminal Procedure

Published on: July 25, 2025

552

Related Experiment Videos

Last Updated: Mar 9, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.0K
Surgical Model for Single-Staged Tissue-Engineered Urothelial Tubes in Minipigs
04:05

Surgical Model for Single-Staged Tissue-Engineered Urothelial Tubes in Minipigs

Published on: July 5, 2024

799
Large Volume Blood Collection from Swine for In Vitro Applications: Use of Intracardiac Cannulation and a Vacuum Pump as a Terminal Procedure
04:09

Large Volume Blood Collection from Swine for In Vitro Applications: Use of Intracardiac Cannulation and a Vacuum Pump as a Terminal Procedure

Published on: July 25, 2025

552

Area of Science:

  • Veterinary Pharmacy
  • Pharmaceutical Compounding
  • Animal Health

Background:

  • Limited availability of approved veterinary drugs necessitates extemporaneous preparation (compounding).
  • Veterinary compounding primarily serves companion animals to prevent drug residues in food-producing animals.
  • Compounded therapies offer benefits but pose risks from poor quality or species-specific toxic excipients.

Conclusions:

  • High-quality veterinary compounding is vital for animal health.
  • Addressing regulatory inconsistencies and improving formula validation are key.
  • Resources and adherence to standards can mitigate risks in veterinary drug compounding.